(603229)"Zhejiang Ausun Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603229 · · 12 pages · Chinese
Summary by 6ix AI
The report includes a summary of major accounting data and financial indicators, along with changes and reasons for these variations. It also provides insights into the company's total assets and equity attributable to shareholders at the end of the reporting period.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Ausun Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Ausun Pharmaceutical
- Announcement on Provision for Asset Impairment and Credit Impairment for the First Half of 2026
- Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Overseas Marketing Authorization of the Cooperative Product
- Announcement on Obtaining Approval for Marketing of Chemical APIs
Later from Zhejiang Ausun Pharmaceutical
- (603229)"Zhejiang Ausun Pharmaceutical Co., Ltd."Announcement on Obtaining Overseas Marketing Authorization for Cooperative Product
- (603229)"Zhejiang Ausun Pharmaceutical Co., Ltd."Announcement on Appointment of Board Secretary
Follow Zhejiang Ausun Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Ausun Pharmaceutical